Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 10—October 2005

Research

Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci Co-colonization1

Jon P. Furuno*Comments to Author , Eli N. Perencevich*†‡, Judith A. Johnson*†, Marc-Oliver Wright‡2, Jessina C. McGregor*, J. Glenn Morris*†, Sandra M. Strauss*, Mary-Claire Roghman*†, Lucia L. Nemoy*†, Harold C. Standiford‡, Joan N. Hebden‡, and Anthony D. Harris*†‡
Author affiliations: *University of Maryland School of Medicine, Baltimore, Maryland, USA; †Veterans' Affairs Maryland Health Care System, Baltimore, Maryland, USA; ‡University of Maryland Medical Center, Baltimore, Maryland, USA

Main Article

Table 3

Outcomes of patients co-colonized with VRE and MRSA*

Outcome MRSA/VRE co-colonization, n = 65 No co-colonization, n = 2,375 p value
Death, n (%) 16 (24.6) 420 (17.7) 0.15
Mean length (d) of hospital stay (SD) 12.0 (16.5) 14.0 (17.8) 0.37
Subsequent MRSA-positive clinical culture, n (%) 2 (3.1) 34 (1.4) <0.01
Subsequent VRE-positive clinical culture, n (%) 2 (3.1) 39 (1.6) 0.38
Discharge location
Home or self-care, n (%) 27 (41.5) 1,467 (61.8) <0.01
Hospital, n (%) 21 (32.3) 368 (15.5) <0.01
Rehabilitation facility, n (%) 1 (1.5) 62 (2.6) 0.59
Unknown, n (%) 0 18 (0.8) 0.48

*VRE, vancomycin-resistant enterococci; MRSA, methicillin-resistant Staphylococcus aureus; SD, standard deviation.

Main Article

1These data were presented in part at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, September 2004.

2Current affiliation: Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA.

TOP